BCAX (Bicara Therapeutics) 3-1 Month Momentum %: -4.31% (As of Jul. 12, 2026)


BCAX Bicara Therapeutics Inc BCAX
12 GF Score
Price $28.88
! 3 Warning Signs
View Full Analysis

What is Bicara Therapeutics 3-1 Month Momentum %?

Bicara Therapeutics BCAX -2.59% 12 3-1 Month Momentum % is -4.31% as of Jul. 12, 2026. GuruFocus rates BCAX with a GF Score™ of 12/100. The stock has 3 warning signs investors should review. Among 1,385 Biotechnology companies, Bicara Therapeutics ranks better than 58.63% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-12), Bicara Therapeutics's 3-1 Month Momentum % is -4.31%.

The industry rank for Bicara Therapeutics's 3-1 Month Momentum % or its related term are showing as below:

BCAX's 3-1 Month Momentum % is ranked better than
58.63% of 1385 companies
in the Biotechnology industry
Industry Median: -10.98 vs BCAX: -4.31

Bicara Therapeutics  (NAS:BCAX) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Bicara Therapeutics 3-1 Month Momentum % Related Terms

BCAX vs ZYME, SRPT, INVA: 3-1 Month Momentum % Comparison

For the Biotechnology subindustry, Bicara Therapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bicara Therapeutics 3-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bicara Therapeutics's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Bicara Therapeutics's 3-1 Month Momentum % falls into.


BCAX
12GF Score
Bicara Therapeutics Inc BCAX
3-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bicara Therapeutics  (NAS:BCAX) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of -4.31% mean?
Bicara Therapeutics (BCAX) has a 3-1 Month Momentum % of -4.31% as of Jul. 12, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Bicara Therapeutics and its competitors. According to the industry distribution chart, Bicara Therapeutics ranks #573 out of 1385 companies in the Biotechnology industry, placing it in the top 41.4%.
Is Bicara Therapeutics' 3-1 Month Momentum % too high?
Bicara Therapeutics' current 3-1 Month Momentum % is -4.31%. Based on the distribution chart, Bicara Therapeutics ranks #573 out of 1385 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Bicara Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bicara Therapeutics' 3-1 Month Momentum % compare to ZYME and SRPT?
According to the Biotechnology industry distribution chart, Bicara Therapeutics ranks #573 out of 1385 companies for 3-1 Month Momentum %. This puts Bicara Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Bicara Therapeutics and its competitors. Bicara Therapeutics's current 3-1 Month Momentum % is -4.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bicara Therapeutics stock overvalued right now?
Bicara Therapeutics (BCAX) has a current 3-1 Month Momentum % of -4.31%. The current 3-1 Month Momentum % is -4.31%. Bicara Therapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Bicara Therapeutics (BCAX), the current 3-1 Month Momentum % is -4.31% as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bicara Therapeutics Business Description

Address 116 Huntington Avenue, Suite 703, Boston, MA, USA, 02116
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
12GF Score

Get the complete analysis for BCAX

3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.88
Price